Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance

Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance

On-Demand Webcast

Corey J. Langer, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


Charu Aggarwal, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Lyudmila Bazhenova, MD
University of California San Diego
San Diego, California

Helen J. Ross, MD
Mayo Clinic
Phoenix, Arizona

Target Audience

This educational activity is designed for medical oncologists, health-system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other clinicians involved and/or interested in the therapeutic management of patients with NSCLC.


Compared with other cancers, NSCLC has shown a higher rate of genetic mutations. The most-frequently studied genetic alterations are the epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Both are involved in the receptor tyrosine kinase signaling pathway, a mechanism that contributes to cancer cell survival and proliferation. Between 80% and 90% of EGFR somatic mutations display a deletion to exon 19 (del19) and substitutions to exon 21 L858R. These mutations have provided a therapeutic target for EGFR tyrosine kinase inhibitors (TKIs), which have vastly expanded treatment opportunities for patients with EGFR+ NSCLC. Clinicians who treat patients with NSCLC need to understand the genetic targets of newer second-generation and third-generation EGFR TKIs.

This webcast aims to improve oncology clinicians’ ability to treat patients with EGFR+ NSCLC, specifically as it relates to incorporating newer therapies and clinical data into practice and actively monitoring and addressing treatment resistance and related adverse events.


Upon successful completion of this educational activity, participants should be better able to:

  1. Review the current and emerging clinical data regarding the treatment NSCLC that harbor genetic mutations such as EGFR, ALK, ROS1, and less commonly ERBB2, HER2, BRAF, KRAS, MET, TRK, and RET
  2. Determine the clinical relevance of emerging efficacy and safety data from trials evaluating targeted therapies and immune checkpoint inhibitors (alone or in combination) for NSCLC, SCLC, mesothelioma, and less common thoracic malignancies
  3. Evaluate the role of current and emerging biomarkers as predictive indicators for treatment selection and patient response
  4. Translate the latest evidence regarding molecularly targeted agents, immunotherapies, and predictive biomarkers to informed and personalized NSCLC treatment plans

Release Date: October 31, 2018

Expiration Date: October 31, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by an educational grant from Pfizer.


Imedex is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Imedex designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 credits.

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours.


This knowledge-based activity (JA0006201-9999-18-209-H01-P) is approved for 1.50 contact hours (0.015 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period. 

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Charu Aggarwal, MD, Lyudmila Bazhenova, MD, Corey J. Langer, MD, Helen J. Ross, MD; and Chris Bolwell, Manjusha Sala, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Charu Aggarwal, MD has served as a consultant for Bristol-Myers Squibb, Celgene, and Roche.

Lyudmila Bazhenova, MD has received research and/or grant support from Pfizer and Takeda, and has served as a consultant for AbbVie, Janssen, Pfizer, Takeda, Targetpharmasolutions, Theravance, and UCB.

Corey J. Langer, MD has received research and/or grant support from Advantagene, Ariad (Takeda), Celgene, Clovis, Eli Lilly and Company, Genetech/Roche, GlaxoSmithKline, Incyte, Inovio, Marcrogenics, Merck, Nektar, OSI Pharmaceuticals, Inc., Pfizer Inc, and Stemcentrx (Abbvie), has served as a consultant for Abbott Laboratories, Ariad (Takeda), AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc., Biodesix, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, CarisDx, Celgene, Clariant, Clovis, Eli Lilly and Company, Genetech/Roche, ImClone Systems Incorporated, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Synta Pharmaceuticals Corp, has participated in a speaker's bureau for CCO, NOCR, PER, PIK, and RTP, and has received other support from Amgen, Eli Lilly and Company, Incyte, Peregrine, SWOG, and Synta Pharmaceuticals Corp

Helen J. Ross, MD did not report any financial relationships. 

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Manjusha Sala and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME and Imedex require faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.